In New Jersey, an adult can walk into a licensed dispensary and legally buy six ounces of cannabis. That same adult, growing a single plant in a spare bedroom, is committing a third-degree crime — three to five years and a fine of up to $25,000, per NORML's reading of N.J.S.A. 2C:35-5. Ten plants moves it to the second degree.
Two bills in Trenton would end that. Neither has moved, and on September 20 and 22 patient advocates went public over the Governor's silence. That is the news. Here is the part that matters to you: a buyer underwriting your store this quarter has to put a number on home grow, and if you have not put one there yourself, they will choose it for you.
What is actually on the table
The bills are S2564 and S1758, both sponsored by Senators Vin Gopal (D-11) and Troy Singleton (D-7). S2564 is the broad one: up to six plants for personal recreational use by an adult 21 or older, up to ten for a registered medical patient, twelve per household. S1758 is the narrow one — registered patients only, four mature and four immature plants — and it carries an unusually bipartisan roster, including Senate Republican Minority Leader Anthony Bucco (R-25) and Health Committee Chair Joe Vitale (D-19).
Neither is moving. Heady NJ reported on September 20 that both are stalled over opposition from Senate President Nick Scutari, the architect of the adult-use law in the first place. Two days later, The Marijuana Herald reported that Sue DeGregorio-Rosen of Sativa Cross and the NJ Homegrowing Coalition had gone public: "We have reached out to the Governor and her team through many different avenues, only to be met with complete silence." Governor Sherrill campaigned on supporting home cultivation with what she called "common-sense regulations, safeguards and limits."
As of August 2026, New Jersey and Delaware are the only adult-use states permitting no home cultivation at all. Everywhere else allows some version of it.
Scenario one: nothing moves
The bills die with the session. This is what your current numbers already reflect, and what most sellers quietly assume when they set an asking price.
Top line: unchanged. Margin: unchanged. What a buyer does with it: nothing — which is the problem. A buyer assuming this is paying full price for a policy bet they never consciously made. Sophisticated buyers price all three and blend.
Scenario two: medical only
S1758 passes, or something like it. Four mature and four immature plants, registered patients only — a narrow population by definition, not the adult-use customer driving your volume.
Top line: low single digits at most, concentrated in whatever medical share your mix still carries. Margin: effectively unchanged. What a buyer does with it: nothing to the multiple. It is a rounding error next to price compression, which has already walked flower from $12.49 a gram in January 2024 down to $8.09.
Scenario three: six plants, twelve per household
This is the one owners worry about, and the worry is mostly misplaced. The best evidence comes from Canada, which legalized four-plant home cultivation nationally in 2018. Research published in Addictive Behaviors Reports and summarized by NORML found roughly nine to ten percent of Canadian cannabis consumers reported growing at home in 2020, up from about six percent before legalization. Quebec and Manitoba, the two provinces that banned it, sat among the lowest rates.
Notice what that number is and is not. It is the share of consumers who grow something, not the share of consumption coming out of a closet. Somebody growing four plants badly still buys most of what they use. Growing well is a skill, it needs a room, and it takes months. Your most valuable customer — the one assembling a $47 basket twice a week on the way home — is almost never that person.
Top line: model low-to-mid single-digit erosion phased over two to three years, weighted toward heavy users. Margin: mild pressure, because the customers you lose skew toward bulk flower, your thinnest category. What a buyer does with it: here is where it lands — not in the revenue forecast, in the discount rate. A buyer who believes this is coming shaves the multiple rather than the projection, because no amount of diligence resolves it.
The comparison nobody makes
New York permits six plants per adult and twelve per household. It also has more than 600 licensed dispensaries and $3.3 billion in cumulative sales, per the Governor's office in March 2026. Home cultivation did not stop that market from getting built. What has held New York back is unlicensed competition — a different problem, and the real one here too. The customer buying outside the legal market is already doing it. Legal home grow does not create that person; it gives a small slice of them a lawful alternative.
One more thing if you are underwriting a long hold: when Quebec's outright ban was challenged, the Supreme Court of Canada upheld it unanimously in 2023. The analogy is imperfect and the law here is your attorney's question, not mine — but bans on home cultivation do not automatically fall.
- What share of your revenue is bulk flower? That is the exposed line. Pull the last twelve months by category and write the number down.
- What share of your gross profit comes from your top ten percent of customers? If it is concentrated, this question is smaller than it feels.
- How much of your basket is convenience? Vapes, edibles, pre-rolls and anything a home grower cannot make at a kitchen table are your insulation.
- What does a change in law do to your LOI? Ask your cannabis attorney how a bill passing mid-diligence would read against your representations.
- Have you modelled this yourself? A seller who hands a buyer a scenario table controls that conversation. A seller who does not gets handed one.
What the unpriced version costs
Here is the arithmetic that decides it. New Jersey dispensaries change hands at roughly three to six times EBITDA, most closed deals landing between four and six. On a store producing $600,000 of EBITDA, one turn is $600,000. A buyer who marks you down half a turn for policy risk nobody quantified has taken $300,000 off your price — considerably more than any realistic home-grow effect costs you across their first three years.
That is the trade. The risk is small. The unpriced risk is expensive. The only way to stop a buyer picking the number is to arrive with your own. For the rest of how that multiple gets assembled, I walked the full stack in what a New Jersey dispensary is actually worth.
I have watched more owners lose value to a risk they could not describe than to a risk that ever arrived. In New Jersey right now, home grow is that risk. Two bills, no movement, a Governor who has not spoken, a Senate President who does not want it — and meanwhile a line in every buyer's model waiting to be filled in. Fill it in yourself, with your own category data, before somebody fills it in for you.
And keep the sizing honest. The operators behind the New Jersey stores that quietly closed this year were not killed by policy. They were killed by margin. Policy just showed up while they were already thin. If you want to know where your store actually sits on that question, that is a conversation, not a spreadsheet — see what is moving in New Jersey right now, or call me.